Literature DB >> 24042205

Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?

Jocelyn Tan-Shalaby1.   

Abstract

A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease. At progression he was given salvage chemotherapy consisting of 5-fluorouracil and leucovorin and went into complete radiographic remission after 12 cycles of treatment. He did develop a portal vein thrombosis but nevertheless his hepatic lesions continued to resolve. Throughout his therapy α-fetoprotein (AFP) levels decreased only minimally. He did not seek retreatment after 14 cycles of chemotherapy and presented 3 months later with relapsed disease on CT scans with markedly elevated AFP levels. He received one more chemotherapy cycle but was unable to tolerate further treatment, succumbing to his disease 3 months thereafter, and a total of 29 months after he was deemed a sorafenib failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24042205      PMCID: PMC3794132          DOI: 10.1136/bcr-2013-010362

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Authors:  Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?

Authors:  Gilles Boschetti; Thomas Walter; Valérie Hervieu; Philippe Cassier; Catherine Lombard-Bohas; Mustapha Adham; Jean-Yves Scoazec; Jérôme Dumortier
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-08       Impact factor: 2.566

3.  Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.

Authors:  Guido Poggi; Benedetta Montagna; Fabio Melchiorre; Pietro Quaretti; Angelo Delmonte; Alberto Riccardi; Barbara Tagliaferri; Federico Sottotetti; Pamela Di Cesare; Maria Giulia Stella; Laura Villani; Michele Zorzetto; Giorgio Greco; Gianpaolo Cornalba; Giovanni Bernardo
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

4.  Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.

Authors:  Ji-Won Kim; Jeong-Ok Lee; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  Am J Clin Oncol       Date:  2011-04       Impact factor: 2.339

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.